middle.news
How Will Optiscan’s $17.75M Entitlement Offer Reshape Its Medical Device Future?
1:06am on Saturday 30th of August, 2025 AEST
•
Healthcare
Read Story
How Will Optiscan’s $17.75M Entitlement Offer Reshape Its Medical Device Future?
1:06am on Saturday 30th of August, 2025 AEST
Key Points
Pro-rata renounceable entitlement issue at $0.085 per share
Offer fully underwritten by major shareholder Peters Investments
Funds earmarked for clinical studies, FDA approvals, and endomicroscope development
Potential dilution of approximately 20% for non-participating shareholders
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Optiscan Imaging (ASX:OIL)
OPEN ARTICLE